Alberta Investment Management Corp (AIMCo)’s Catalyst Pharmaceutical CPRX Stock Holding History

Alberta Investment Management Corp (AIMCo)’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-101,700	Closed	-$1.71M	–	1025
2023 Q4	$1.71M	Buy	101,700 +33,900	+50%	+$463K	0.02%	481
2023 Q3	$793K	Sell	67,800 -31,581	-32%	-$422K	0.01%	703
2023 Q2	$1.34M	Hold	99,381	–	–	0.01%	660
2023 Q1	$1.65M	Hold	99,381	–	–	0.02%	604
2022 Q4	$1.85M	Sell	99,381 -124,431	-56%	-$1.92M	0.02%	653
2022 Q3	$2.87M	Sell	223,812 -15,983	-7%	-$189K	0.02%	622
2022 Q2	$1.68M	Sell	239,795 -28,217	-11%	-$207K	0.01%	757
2022 Q1	$2.22M	Buy	268,012 +89,312	+50%	+$631K	0.01%	756
2021 Q4	$1.21M	Hold	178,700	–	–	0.01%	707
2021 Q3	$947K	Buy	178,700 +59,900	+50%	+$328K	0.01%	792
2021 Q2	$683K	Buy	+118,800	New	+$613K	0.01%	829
2020 Q4	–	Sell	-80,000	Closed	-$238K	–	893
2020 Q3	$238K	Hold	80,000	–	–	﹤0.01%	908
2020 Q2	$370K	Buy	+80,000	New	+$359K	﹤0.01%	894
2019 Q4	–	Sell	-55,100	Closed	-$293K	–	939
2019 Q3	$293K	Buy	+55,100	New	+$294K	﹤0.01%	817

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alberta Investment Management Corp (AIMCo)'s CPRX Position: Q1 2024 in Review

Alberta Investment Management Corp (AIMCo) sold out of Catalyst Pharmaceutical (CPRX) in Q1 2024, closing a stake of 101,700 shares — an estimated $1.71M sold.

Alberta Investment Management Corp (AIMCo) first reported a position in CPRX in Q3 2019 and held it in 14 quarters. The position peaked at $2.87M in Q3 2022. 269 funds tracked by Wall St. Rank hold CPRX as of Q1 2024.

Alberta Investment Management Corp (AIMCo) reported no remaining Catalyst Pharmaceutical position as of Q1 2024 after selling out during the quarter.
Alberta Investment Management Corp (AIMCo) sold 101,700 Catalyst Pharmaceutical shares in Q1 2024, an estimated $1.71M.
Alberta Investment Management Corp (AIMCo) first reported a position in Catalyst Pharmaceutical in Q3 2019 and held it in 14 quarters.
Alberta Investment Management Corp (AIMCo)'s Catalyst Pharmaceutical position peaked at $2.87M in Q3 2022.
269 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2024.

Based on Alberta Investment Management Corp (AIMCo)'s 13F filing for Q1 2024, filed 15 May 2024.